Amneal Pharmaceuticals vs Phibro Animal Health
AMRX and PAHC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and PAHC compare
Amneal Pharmaceuticals is the larger company, worth 4.8 times as much as Phibro Animal Health ($6.8B against $1.4B).
On earnings, Phibro Animal Health is cheaper: it trades at 14.4× trailing earnings, against 43.3× for Amneal Pharmaceuticals.
Phibro Animal Health grew revenue faster over the last twelve months (17.1% versus 9.3% for Amneal Pharmaceuticals).
Phibro Animal Health keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with 5.0% at Amneal Pharmaceuticals.
Phibro Animal Health pays a dividend yielding 1.4%; Amneal Pharmaceuticals does not pay one.
Phibro Animal Health scores higher on the StockData Score (22 against 10 for Amneal Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | PAHC |
|---|---|---|
| Size and price | ||
| Market cap | $6.8B | $1.4B |
| Share price | $21.23 | $35.02 |
| Change, 1 year | 84.3% | −21.7% |
| Change, 5 years | 400% | 67.7% |
| Beta (5Y) | 0.90 | −0.07 |
| Employees | 8,500 | 2,605 |
| StockData Score | ||
| Total score | 10 | 22 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 5 | 6 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 43.3× | 14.4× (better) |
| P/S | 2.2× | 0.9× (better) |
| P/B | 205× | 3.7× (better) |
| EV/EBITDA | 20.3× | 5.4× (better) |
| P/FCF | 53.0× (better) | 144× |
| PEG | – | 0.33 |
| FCF yield | 1.9% (better) | 0.69% |
| Fair value | $13.07 | $65.45 |
| Margin of safety | −62.4% | 46.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.3% | 17.1% (better) |
| Revenue growth, 5Y average | 8.7% | 12.7% (better) |
| Net income growth (TTM) | 4563% (better) | 107% |
| EPS growth (TTM) | 4800% (better) | 104% |
| EPS growth, 5Y average | −18.5% | 12.6% (better) |
| Profitability | ||
| Gross margin | 39.3% (better) | 33.8% |
| Operating margin | 14.6% (better) | 12.8% |
| Net margin | 5.0% | 6.6% (better) |
| FCF margin | 4.1% (better) | 0.65% |
| Return on equity | – | 29.7% |
| Return on invested capital | 20.3% | 24.7% (better) |
| Financial health | ||
| Debt / equity | 77.83 | – |
| Net debt / EBITDA | 5.38 | – |
| Interest coverage | – | 4.2× |
| Current ratio | 2.20 | 2.96 (better) |
| Altman Z-score | 2.49 | 3.03 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.4% |
| Payout ratio | – | 19.5% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Shareholder yield | 0.00% | 1.4% (better) |
| Ownership | ||
| Held by institutions | 52.7% | 51.8% |
| Held by insiders | 60.7% | 98.9% |
| Insider net buying, 12 months | −$7.7M (better) | −$23.0M |
| Short interest, % of float | 9.1% | 233% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- PAHC stock overview
- PAHC income statement
- PAHC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.